These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33504237)

  • 21. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
    Maurer M; Khan DA; Elieh Ali Komi D; Kaplan AP
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1067-1078. PubMed ID: 33685605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
    Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
    Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab: what benefits should we expect?
    Giménez-Arnau A; Velasco M; Armario Hita JC; Labrador-Horrillo M; Silvestre Salvador JF
    Eur J Dermatol; 2016 Aug; 26(4):340-4. PubMed ID: 27210073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria.
    Matsubara D; Takahagi S; Saito R; Kamegashira A; Tanaka A; Hide M
    J Dermatol; 2021 Jan; 48(1):56-63. PubMed ID: 33029864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis.
    Shaker M; Oppenheimer J; Wallace D; Lang DM; Rambasek T; Dykewicz M; Greenhawt M
    J Allergy Clin Immunol Pract; 2020; 8(7):2360-2369.e1. PubMed ID: 31751758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab.
    Spertino J; Curto Barredo L; Rozas Muñoz E; Figueras Nart I; Gimenez Arnau A; Serra Baldrich E; Bonfill-Ortí M; Expósito-Serrano V; Guilabert A; Melé Ninot G; Villar Buil M; Garcias Ladaria J; García Navarro X; Vilavella M; Bielsa Marsol I; Aparicio Ortiz G; Baliu Piqué C; Álvarez Abella A; Lamas Domenech N; Mascaró JM; Gómez S; Torné Gutiérrez JI; Vicente Villa A; Gimenez Arnau A
    Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):771-776. PubMed ID: 30107875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature.
    Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB
    Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
    Asero R; Marzano AV; Ferrucci S; Cugno M
    Int Arch Allergy Immunol; 2017; 172(1):40-44. PubMed ID: 28219067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
    Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
    J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
    Wieder S; Maurer M; Lebwohl M
    Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
    Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologics for chronic spontaneous urticaria: toward a personalized treatment.
    Asero R; Ferrucci S; Tedeschi A; Cugno M
    Expert Rev Clin Immunol; 2022 Dec; 18(12):1297-1305. PubMed ID: 36264653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
    Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
    J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying Patients for Self-Administration of Omalizumab.
    Murphy KR; Winders T; Smith B; Millette L; Chipps BE
    Adv Ther; 2023 Jan; 40(1):19-24. PubMed ID: 36173511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.